Evidence map›Paper›PMID 42469829›Full record

ArticleCancer cell international2026

FOXA2 suppresses ESCC proliferation and metastasis by inhibiting PSMB9 expression, thereby attenuating proteasome activity.

Wenqiang Xia, Ning Li, Chunxia Gong, Xin Li, Hao Li, Bowen Shi, Hezhong Chen

Abstract read
In one paragraph

Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wenqiang Xia *Department of Thoracic Surgery, The First Affiliated Hospital of Naval Medical University, Naval Medical University, Changhai Road, Shanghai, 200433, China.
Ning Li *Department of Cardiothoracic Surgery, Naval Medical Center of PLA, Naval Medical University, Shanghai, 200052, China.
Chunxia Gong *Department of Thoracic Surgery, The First Affiliated Hospital of Naval Medical University, Naval Medical University, Changhai Road, Shanghai, 200433, China.
Xin LiDepartment of Thoracic Surgery, The First Affiliated Hospital of Naval Medical University, Naval Medical University, Changhai Road, Shanghai, 200433, China.
Hao LiDepartment of Thoracic Surgery, The First Affiliated Hospital of Naval Medical University, Naval Medical University, Changhai Road, Shanghai, 200433, China.
Bowen ShiDepartment of Thoracic Surgery, The First Affiliated Hospital of Naval Medical University, Naval Medical University, Changhai Road, Shanghai, 200433, China. bowen_shi@126.com.
Hezhong ChenDepartment of Thoracic Surgery, The First Affiliated Hospital of Naval Medical University, Naval Medical University, Changhai Road, Shanghai, 200433, China. drchenhz@163.com.

Funding

234 Discipline Climbing Plan 2020YXK054Natural Science Foundation of Shanghai 20ZR1456200
6 · The paper itself

Abstract

backgroundEsophageal squamous cell carcinoma (ESCC) represents a highly lethal malignancy. The FOXA2 was involved in cellular proliferation, differentiation, tumorigenesis, and metastasis. The precise regulatory mechanisms of FOXA2 in ESCC progression remain unclear. MATERIALS AND

methodsWestern blotting, reverse transcription-quantitative polymerase chain reaction, and immunohistochemistry were used to detect the expression level of FOXA2, CCK-8, transwell, and wound healing assays in vitro and xenograft tumor model in vivo were applied to assess the function of FOXA2. RNA-Seq analysis and the following functional assays were used to elucidate the relationship between FOXA2 and proteasome activity.

resultsThe expression level of FOXA2 was downregulated in ECSS tissues and cells. Overexpression of FOXA2 in ESCC cells inhibited epithelial-mesenchymal transition in ESCC cells with the upregulation of E-cadherin and downregulation of Vimentin. Meanwhile, overexpression of FOXA2 inhibited the proliferation, migration, and invasion of ESCC cells. Mechanically, proteasome was involved in the ESCC cells proliferation and invasion inhibition induced by FOXA2, and reduced proteasome activity inhibited ESCC cells proliferation and invasion. RNA-Seq analysis identified PSMB9 as a key downstream target, indicating that FOXA2 attenuates proteasome activity by suppressing PSMB9 expression.

conclusionFOXA2 suppresses ESCC proliferation and invasion by modulating proteasome activity through PSMB9, highlighting its critical role in ESCC progression and its potential as a therapeutic target.

Indexed as

EMTESCCFOXA2ProteasomePSMB9

Identifiers

PMID42469829
PMCPMC13660051

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.